SG Americas Securities LLC Acquires New Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

SG Americas Securities LLC acquired a new stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFSGet Rating) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 19,512 shares of the medical equipment provider’s stock, valued at approximately $444,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Kornitzer Capital Management Inc. KS bought a new stake in BioLife Solutions during the 1st quarter valued at about $655,000. Conestoga Capital Advisors LLC lifted its holdings in BioLife Solutions by 10.9% during the 1st quarter. Conestoga Capital Advisors LLC now owns 57,365 shares of the medical equipment provider’s stock valued at $1,304,000 after buying an additional 5,655 shares in the last quarter. Zweig DiMenna Associates LLC lifted its holdings in BioLife Solutions by 18.8% during the 1st quarter. Zweig DiMenna Associates LLC now owns 376,550 shares of the medical equipment provider’s stock valued at $8,559,000 after buying an additional 59,567 shares in the last quarter. Truist Financial Corp bought a new stake in BioLife Solutions during the 1st quarter valued at about $208,000. Finally, NorthCrest Asset Manangement LLC bought a new stake in BioLife Solutions during the 1st quarter valued at about $293,000. Institutional investors own 83.48% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on BLFS shares. Cowen reduced their price target on shares of BioLife Solutions from $50.00 to $32.00 in a report on Tuesday, May 10th. B. Riley reduced their price target on shares of BioLife Solutions from $48.00 to $34.00 in a report on Tuesday, May 17th. Oppenheimer upgraded shares of BioLife Solutions from a “market perform” rating to an “outperform” rating in a report on Monday, April 25th. TheStreet lowered shares of BioLife Solutions from a “c-” rating to a “d” rating in a report on Tuesday, April 12th. Finally, Maxim Group reduced their price target on shares of BioLife Solutions from $60.00 to $30.00 in a report on Thursday, May 12th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $42.17.

BioLife Solutions Stock Up 0.6 %

Shares of BioLife Solutions stock opened at $21.49 on Friday. The firm’s 50 day moving average price is $15.94 and its 200-day moving average price is $19.00. The company has a quick ratio of 2.53, a current ratio of 3.39 and a debt-to-equity ratio of 0.01. BioLife Solutions, Inc. has a 52-week low of $10.40 and a 52-week high of $60.67. The company has a market cap of $911.39 million, a P/E ratio of -61.40 and a beta of 1.99.

BioLife Solutions (NASDAQ:BLFSGet Rating) last issued its quarterly earnings data on Monday, May 9th. The medical equipment provider reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The firm had revenue of $36.22 million during the quarter, compared to analysts’ expectations of $37.87 million. BioLife Solutions had a negative return on equity of 6.24% and a negative net margin of 10.35%. During the same period in the previous year, the firm earned $0.01 EPS. On average, sell-side analysts predict that BioLife Solutions, Inc. will post -0.67 EPS for the current fiscal year.

Insiders Place Their Bets

In other BioLife Solutions news, CRO Marcus Schulz sold 4,600 shares of the business’s stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $20.03, for a total transaction of $92,138.00. Following the sale, the executive now owns 36,218 shares of the company’s stock, valued at approximately $725,446.54. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other BioLife Solutions news, CRO Marcus Schulz sold 4,600 shares of the business’s stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $20.03, for a total transaction of $92,138.00. Following the sale, the executive now owns 36,218 shares of the company’s stock, valued at approximately $725,446.54. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Greef Roderick De sold 9,158 shares of the business’s stock in a transaction that occurred on Tuesday, July 12th. The stock was sold at an average price of $15.79, for a total transaction of $144,604.82. Following the sale, the chief operating officer now directly owns 124,458 shares in the company, valued at approximately $1,965,191.82. The disclosure for this sale can be found here. In the last quarter, insiders have sold 19,678 shares of company stock valued at $325,403. Insiders own 5.90% of the company’s stock.

About BioLife Solutions

(Get Rating)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

See Also

Want to see what other hedge funds are holding BLFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioLife Solutions, Inc. (NASDAQ:BLFSGet Rating).

Institutional Ownership by Quarter for BioLife Solutions (NASDAQ:BLFS)

Want More Great Investing Ideas?

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.